-
Subject Areas on Research
-
(4-[18F]fluoro-3-iodobenzyl)guanidine, a potential MIBG analogue for positron emission tomography.
-
1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation.
-
3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.
-
5-Fluorouracil in childhood solid tumors.
-
A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells.
-
A new activity of doublecortin in recognition of the phospho-FIGQY tyrosine in the cytoplasmic domain of neurofascin.
-
A novel basal promoter element is required for expression of the rat tyrosine hydroxylase gene.
-
A novel intensive induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support.
-
Amyloid precursor protein and amyloid beta-peptide bind to ATP synthase and regulate its activity at the surface of neural cells.
-
An exploratory study of environmental and medical factors potentially related to childhood cancer.
-
Analysis of oxygen/glucose-deprivation-induced changes in SUMO3 conjugation using SILAC-based quantitative proteomics.
-
Anaplastic renal cell carcinoma following neuroblastoma.
-
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.
-
Antigens shared by rat schwannomas, neuroblastomas, and a testicular interstitial cell carcinoma.
-
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
-
ApoJ/Clusterin concentrations are determinants of cerebrospinal fluid cholesterol efflux capacity and reduced levels are associated with Alzheimer's disease.
-
Bilateral adrenal neuroblastoma.
-
Binding of tissue-type plasminogen activator to the glucose-regulated protein 78 (GRP78) modulates plasminogen activation and promotes human neuroblastoma cell proliferation in vitro.
-
Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models.
-
Brain tumors induced in dogs by the Schmidt-Ruppin strain of Rous sarcoma virus. Neuropathological and immunological observations.
-
COMT gene locus: new functional variants.
-
Caspase-8 levels correlate with the expression of signal transducer and activator of transcription 1 in high-grade but not lower grade neuroblastoma.
-
Catabolism of 4-fluoro-3-iodobenzylguanidine and meta-iodobenzylguanidine by SK-N-SH neuroblastoma cells.
-
Ciliary neurotrophic factor receptor alpha mRNA in NB41A3 neuroblastoma cells: regulation by cAMP.
-
Circulating vitamin D concentration and risk of seven cancers: Mendelian randomisation study.
-
Clear cell sarcoma of the gastrointestinal tract after very low-dose therapeutic radiation therapy: a case report.
-
Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma.
-
Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program.
-
Common genetic variants associated with telomere length confer risk for neuroblastoma and other childhood cancers.
-
Comparing oncologic outcomes after minimally invasive and open surgery for pediatric neuroblastoma and Wilms tumor.
-
Comparison of ¹²³I-metaiodobenzylguanidine (MIBG) and ¹³¹I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group.
-
Comprehensive analysis of chromosome 1p deletions in neuroblastoma.
-
Current concepts. Cancer in children.
-
Cytotoxicity of alpha-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells.
-
Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma.
-
Depletion of catalytic and regulatory subunits of protein kinase CK2 by antisense oligonucleotide treatment of neuroblastoma cells.
-
Detailed molecular analysis of 1p36 in neuroblastoma.
-
Differential regulation of c-jun and CREB by acrolein and 4-hydroxynonenal.
-
Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial.
-
Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma.
-
Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.
-
Evaluation of meta-[211At]astatobenzylguanidine in an athymic mouse human neuroblastoma xenograft model.
-
Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma.
-
Event-free survival of children with biologically favourable neuroblastoma based on the degree of initial tumour resection: results from the Pediatric Oncology Group.
-
Evolving biopsy techniques for the diagnosis of neuroblastoma in children.
-
Ex vivo pediatric brain tumors express Fas (CD95) and FasL (CD95L) and are resistant to apoptosis induction.
-
Expression and mutation analysis of the Wilms' tumor 1 gene in human neural tumors.
-
Expression and regulation of calcium-independent protein kinase C in NG 108-15 cell differentiation.
-
Expression of p53 in human neuroblastoma- and neuroepithelioma-derived cell lines.
-
Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines.
-
Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma.
-
Functional analysis of intra-allelic variation at NACP-Rep1 in the alpha-synuclein gene.
-
GD3 expression by cultured human tumor cells of neuroectodermal origin.
-
Ganglioglioma: a clinical study with long-term follow-up.
-
Genetic and pharmacologic identification of Akt as a mediator of brain-derived neurotrophic factor/TrkB rescue of neuroblastoma cells from chemotherapy-induced cell death.
-
Genetic variant rs3750625 in the 3'UTR of ADRA2A affects stress-dependent acute pain severity after trauma and alters a microRNA-34a regulatory site.
-
Genetic variation associated with childhood and adult stature and risk of MYCN-amplified neuroblastoma.
-
Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.
-
Genomic distribution of CHD7 on chromatin tracks H3K4 methylation patterns.
-
Glioneuronal tumors of the central nervous system.
-
Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma.
-
Heparin-binding epidermal growth factor-like growth factor promotes neuroblastoma differentiation.
-
Hepatic metastasis from neuroblastoma.
-
High dose cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors.
-
Histologic maturation of cerebral neuroblastoma following conventional chemotherapy.
-
Human fetal brain antigen expression common to tumors of neuroectodermal tissue origin.
-
Identifying key components of the PrPC-PrPSc replicative interface.
-
Impact of Extent of Resection on Local Control and Survival in Patients From the COG A3973 Study With High-Risk Neuroblastoma.
-
Incidence of anemia in children with solid tumors or Hodgkin disease.
-
Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.
-
Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.
-
Initial testing of cisplatin by the pediatric preclinical testing program.
-
Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.
-
Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program.
-
Insulin-like growth factor-I is a serum component stimulating growth of human neuroblastoma.
-
Intractable seizures, compulsions, and coprolalia: a pediatric case study.
-
Involvement of gamma and beta actin isoforms in mouse neuroblastoma differentiation.
-
Iodopyridine-for-iodobenzene substitution for use with low molecular weight radiopharmaceuticals: application to m-iodobenzylguanidine.
-
Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity.
-
Long-term psychological and educational outcomes for survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study.
-
Long-term results of therapy for stage C neuroblastoma.
-
MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
-
MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis.
-
Malignant supratentorial glial-neuronal neoplasms: report of two cases and review of the literature.
-
Management of chemotherapy in a pregnancy complicated by a large neuroblastoma.
-
Management of solid tumors in children.
-
Medulloblastoma cell-substrate interaction in vitro.
-
Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines.
-
Minimally invasive surgery for abdominal and thoracic neuroblastic tumors: A systematic review by the APSA Cancer committee.
-
Morphometric analysis for early detection of changes in cellular structure in a toxicological experiment.
-
N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide (ICA-27243): a novel, selective KCNQ2/Q3 potassium channel activator.
-
Nanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastoma.
-
Nanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapy.
-
Neonatal neoplasms.
-
Neuroblastoma grafts are noninvasively removed within mouse neocortex by selective laser activation of intracellular photolytic chromophore.
-
Neuroblastoma in a patient with the Beckwith-Wiedemann syndrome (BWS).
-
Neuroblastoma in a pediatric patient with a microduplication of 2p involving the MYCN locus.
-
Neurotrophins differentially regulate voltage-gated ion channels.
-
New MIBG preparation to improve targeted radiotherapy and reduce toxic side-effects in neuroblastoma patients undergoing combination treatment.
-
No-carrier-added (4-fluoro-3-[131I]iodobenzyl)guanidine and (3-[211At]astato-4-fluorobenzyl)guanidine.
-
No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog.
-
No-carrier-added synthesis of a 4-methyl-substituted meta-iodobenzylguanidine analogue.
-
No-carrier-added synthesis of meta-[131I]iodobenzylguanidine.
-
Non-inferiority of fragmented care for high-risk pediatric neuroblastoma patients: a single institution analysis.
-
Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells.
-
Occurrence of lacto series gangliosides 3'-isoLM1 and 3',6'-isoLD1 in human gliomas in vitro and in vivo.
-
Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales--a report from the Children's Oncology Group.
-
Parc-ing p53 in the cytoplasm.
-
Parkin is not regulated by the unfolded protein response in human neuroblastoma cells.
-
Pediatric radiation oncology.
-
Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group.
-
Phase II study demonstrating failure of both a five-drug continuous-therapy regimen and a two-drug pulse-therapy regimen in the treatment of metastatic neuroblastoma: Southwest Oncology Group Study 822.
-
Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.
-
Phosphorylation of microtubule-associated proteins by protein kinase CK2 in neuritogenesis.
-
Picralima nitida seeds suppress PGE2 production by interfering with multiple signalling pathways in IL-1β-stimulated SK-N-SH neuronal cells.
-
Plasma dopamine-beta-hydroxylase in the diagnosis of neuroblastoma.
-
Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma.
-
Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG).
-
Progress against childhood cancer: the Pediatric Oncology Group experience.
-
Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 Study.
-
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.
-
Radiation therapy in the management of neuroblastoma: the Duke University Medical Center experience 1967-1984.
-
Redox properties of cytochrome oxidase and vascular reactivity of astrocytomas and neuroblastomas in vivo.
-
Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
-
Reply to J. Stenman et al.
-
Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma.
-
Role of phosphorylated MAPlB in neuritogenesis.
-
Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study.
-
SMFM Fetal Anomalies Consult Series #4: Genitourinary anomalies.
-
Selective neuronal cell attachment to a covalently patterned monoamine on fluorinated ethylene propylene films.
-
Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group.
-
Severe encephalopathy associated with ifosfamide administration in two children with metastatic tumors.
-
Sonographic tissue pattern in neuroblastoma.
-
Stage III neuroblastoma over 1 year of age at diagnosis: improved survival with intensive multimodality therapy including multiple alkylating agents.
-
Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth.
-
Synthesis and evaluation of 4-[18F]fluoropropoxy-3-iodobenzylguanidine ([18F]FPOIBG): A novel 18F-labeled analogue of MIBG.
-
Synthesis of carrier-free 131I-meta-iodobenzyl-guanidine by novel routes to enhance therapeutic efficiency in neuroblastoma.
-
Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma.
-
The cloning of a receptor-type protein tyrosine phosphatase expressed in the central nervous system.
-
The effect of Bacopa monnieri on gene expression levels in SH-SY5Y human neuroblastoma cells.
-
The effect of halothane on cultured fibroblasts and neuroblastoma cells.
-
The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization.
-
The tumor dormant state.
-
Therapeutic targets for neuroblastomas.
-
Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions.
-
TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.
-
Type III TGF-β receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma.
-
Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1.
-
Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials.
-
Value of surgical resection in children with high-risk neuroblastoma.
-
Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group.
-
Workshop on monoclonal antibodies against gliomas and other neuroectoderm-derived tumors.
-
Keywords of People